Indicated as part of a three-drug oral combination.
Kevin W. Chamberlin, PharmD
Cariprazine demonstrated greater improvement on the MADRS.
FDA approves lofexidine for opioid withdrawal symptoms.
The FDA recently approved cannabidiol oral solution to treat seizures.
Vabomere combines a carbapenem and a beta-lactamase inhibitor as a treatment for complicated urinary tract infections.
CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.